Notably, we did not observe any macroscopic signs of PD/neuropathy-linked behavioral abnormalities in PAC α-SynA53TTG mice upon CDK14 inhibitor treatment, such as loss of motor activity or imbalance during locomotion (Fig. S4A), implying that higher amounts of cytosolic pS129 α-Syn do not substantially promote cerebral and functional impairments. This evidence concerns the gene CDK14 and Parkinson disease.